[2025] Practice with these RAC-US dumps Certification Sample Questions
Get Instant Access of 100% REAL RAC-US DUMP Pass Your Exam Easily
NEW QUESTION # 16
A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?
- A. Documented agreement
- B. Early collaboration
- C. Frequent communication
- D. Follow-up meeting after submission
Answer: C
NEW QUESTION # 17
Which of the following is NOT required to be included in a marketing application?
- A. Final printed label
- B. Evidence of fee payment
- C. Administrative forms
- D. Quality, safety, and efficacy Information
Answer: B
NEW QUESTION # 18
Which of the following is the MOST desirable timing and approach for a regulatory affairs professional who wants to provide feedback on proposed new regulations?
- A. Before the enactment of the regulation, through formal comments gathering process
- B. After the enactment of the regulation, through the industry representative
- C. After the enactment of the regulation, through a product-specific meeting
- D. Before the enactment of the regulation, through the industry representative
Answer: A
NEW QUESTION # 19
According to WHO, what are the temperature and humidity conditions for a Zone IVb long- term stability study?
- A. 30: C and 75% RH
- B. 25: C and 60% RH
- C. 30 C and 35% RH
- D. 30c C and 65% RH
Answer: A
NEW QUESTION # 20
Which of the following BEST describes the purpose of the ICH?
- A. To discuss and establish common guidelines for safe, effective, and high-quality medicines for the ICH regions
- B. To protect and promote public health through the evaluation and supervision of safe, effective, and high-quality medicines for the ICH regions
- C. To provide scientific evaluation of applications for international marketing authorization for safe, effective, and high-quality medicines for the ICH regions
- D. To lobby for improved industry standards for the development of new safe, effective, and high-quality medicines for the ICH regions
Answer: A
NEW QUESTION # 21
According to the GHTF, which of the following is NOT an exemption rule when evaluating the decision to report an adverse event?
- A. Malfunction occurring before the end of service life of the medical device
- B. Malfunction protection operated correctly
- C. Adverse event caused by patient conditions
- D. Deficiency of a device found by the user prior to patient use
Answer: C
NEW QUESTION # 22
During face-to-face meetings with the regulatory authority to address submission issues, what is the BEST choice for the number of company representatives who should attend?
- A. As many as government attendees
- B. All senior management from the main office
- C. As many as required by international standards
- D. The minimum number of attendees necessary to address the issues
Answer: D
NEW QUESTION # 23
Which question is pertinent to demonstrate a new pharmaceutical's effectiveness during evaluation by a reimbursement agency?
- A. "Has the product been approved for mor&4nan 10 years?"
- B. "Is the product better than currently available alternatives?"
- C. "Is the product an established gold standard?"
- D. "Is the product profitable for the manufacturer?"
Answer: B
NEW QUESTION # 24
A company is currently marketing an implantable orthopedic medical device. The R&D department is planning to change the material used for the implant. The R&D department states that the change does not impact the safety and effectiveness of the product.
What action should the regulatory affairs professional take FIRST?
- A. Write a memo to file since the change does not impact product safety and effectiveness.
- B. Review the content of change and supporting data for the equivalency with the current material.
- C. No action is needed in this situation.
- D. Prepare regulatory submissions that detail the medical device's change in materials.
Answer: B
NEW QUESTION # 25
After numerous failed attempts to decrease an identified risk in a medical device to an acceptable level, the medical device continues to have unacceptable risks. However, the development team wants to continue development. Which is the BEST recommendation to make in this situation?
- A. Add a warning in the IFU.
- B. Discontinue the project.
- C. Perform another risk-benefit analysis.
- D. Redesign the device.
Answer: D
NEW QUESTION # 26
Company X has a patent for an anti-inflammatory drug that will expire in one year. In order to minimize the effect of the patent expiration, which is the BEST action for the company to take?
- A. Develop a generic version of the drug.
- B. Explore litigation strategy for patent infringements on the drug.
- C. Develop a better brand-name drug in the same class.
- D. Conduct a Phase III study for a new unrelated indication of the drug.
Answer: A
NEW QUESTION # 27
In which section of the ICH Common Technical Document will the overview of clinical data appear?
- A. Module 3
- B. Module 4
- C. Module 1
- D. Module 2
Answer: D
NEW QUESTION # 28
Why is it necessary to run supplemental safety pharmacology studies?
- A. To provide adverse reaction reports and the results of the statistical data to the regulatory authority
- B. To substitute the utilization of GLP
- C. To evaluate potential adverse pharmacodynamics effects not addressed by the core battery
- D. To comply with regulatory authority requirements related to clinical studies
Answer: C
NEW QUESTION # 29
Which of the following changes to a drug product is MOST likely to be implemented without prior regulatory authority approval?
- A. Deleting an ingredient of the drug product
- B. Introducing a new analytical method
- C. Deleting a drug substance
- D. Strengthening a precaution to the product labeling
Answer: D
NEW QUESTION # 30
Company X acquires Company Y.
Both companies produce pharmaceuticals distributed globally. A regulatory authority requires that all labeling for Company Y's products be converted to Company X within three months. The regulatory affairs professional at
Company X concludes that it is not feasible to meet this request within the time frame.
Which is the FIRST step that the regulatory affairs professional at Company X should take to address the situation?
- A. Submit as many labeling conversion applications as possible within the time frame and request an extension for the remaining ones.
- B. Request additional resources from senior management in order to complete the labeling conversion within the time frame given by the regulatory authority.
- C. Convene an urgent meeting with internal stakeholders to inform them of the regulatory authority requirement and assign responsibilities.
- D. Develop a plan of action with tasks, timelines, and responsibilities and request an extension period from the regulatory authority.
Answer: D
NEW QUESTION # 31
Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?
- A. "Product X is effective in all patients with arthritis."
- B. "Product X is a guaranteed cure for arthritis."
- C. "Product X is safe for arthritis and without side effects."
- D. "Product X is effective for the treatment of arthritis."
Answer: D
NEW QUESTION # 32
A company is developing a novel drug to combat AIDS. The preliminary results are very promising and include instances of complete remission. The company has been granted patents in multiple countries for the drug. The regulatory affairs professional is asked to prepare a brief report concerning potential problems for marketing of the product worldwide. Which of the following is the MOST important consideration to discuss?
- A. The stability of the drug in all zone conditions
- B. Doha Declaration in the TRIPS Agreement
- C. The time frame in which the patent will expire
- D. International import and export regulations
Answer: A
NEW QUESTION # 33
According to ICH, which of the following components of study information is NOT required in a clinical study report?
- A. List of lECs or lRBs
- B. Protocol and protocol amendments
- C. Randomization scheme and codes
- D. Detailed CV of all investigators
Answer: D
NEW QUESTION # 34
SOPs for preventive and corrective actions MUST include the procedure to eliminate which of the following?
- A. Causes of non-conformities
- B. Adverse environmental impacts
- C. Inadequate training
- D. Late and/or incorrect deliverables
Answer: A
NEW QUESTION # 35
During the review of a design dossier, the reviewer asks why the company has only carried out a top-down risk approach. The reviewer is referring to which of the following?
- A. Fault tree analysis
- B. ISO 14971 risk analysis
- C. Hazard and operability study
- D. Failure mode and effect analysis
Answer: B
NEW QUESTION # 36
According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood glucose self-testing kit?
- A. Class B
- B. Class C
- C. Class A
- D. Class D
Answer: B
NEW QUESTION # 37
Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?
- A. Subject is hospitalized for the purpose of product administration.
- B. Subject's hospitalization is prolonged during the clinical trial.
- C. Subject is hospitalized due to complications of the product administration.
- D. Subject's hospitalization is due to an unscheduled hip operation.
Answer: A
NEW QUESTION # 38
A process is ultimately validated to ensure which of the following?
- A. The process meets the regulatory requirements.
- B. The process consistently produces the desired results.
- C. The process meets the quality system requirements.
- D. The process consistently meets the desired Quantity standards
Answer: B
NEW QUESTION # 39
......
To be eligible to take the RAC-US exam, candidates must have a minimum of 3 years of regulatory experience in the healthcare industry. Candidates must also meet certain educational requirements, which may vary depending on their level of experience. RAC-US exam is open to individuals from all countries, and there are no restrictions on nationality or location.
Free Exam Files Downloaded Instantly: https://www.vceengine.com/RAC-US-vce-test-engine.html
RAC-US Free Exam Questions with Quality Guaranteed: https://drive.google.com/open?id=1AarYADA27yWNX6SGM-OkctWVBdk9Mar8
